Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-03-08
2005-03-08
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S272000, C514S269000, C514S318000, C514S333000, C514S341000, C546S275400, C546S276100, C546S193000, C544S180000, C544S238000, C544S322000, C544S364000, C544S106000, C544S182000, C544S405000, C544S298000, C544S309000, C544S316000
Reexamination Certificate
active
06864252
ABSTRACT:
The present invention relates to hydrazinyl and nitrogen oxide pyrazoles of the formula I:wherein the ring of the formula (R5)-A-(SOmR4), m, X, R1through R5are as defined in the specification, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the invention are useful in the treatment or alleviation of inflammation and other inflammation associated disorders, such as arthritis, colon cancer and Alzheimer's disease in mammals, preferably humans, dogs, cats and livestock animals.
REFERENCES:
patent: 1104758 (2000-11-01), None
patent: 1104759 (2000-11-01), None
patent: 1104760 (2000-11-01), None
patent: WO9711704 (1997-04-01), None
patent: WO0066562 (2000-11-01), None
patent: WO0140216 (2001-06-01), None
patent: WO0164669 (2001-09-01), None
Chaby (Drug Discovery Today 4(5) 209-221, 5/1999.*
Opal et al. (Infectious Disease Clinics of North America 13(2), pp. 285-297, 6/1999.*
Chalmers (TiPS vol. 17, pp. 166-172 Apr. 1996.*
Cashin, et al., “The pharmacology of benoxaprofen (2-[4-chlorophenyl]-α-methyl-5-benzoxazole acetic acid), LRCL 3794, a new compound with anti-inflammatory activity apparently unrelated to inhibition of prostaglandin synthesis”,J.Pharm.Pharmac., 29, pp. 330-336 (1977).
Ezer, et al., “Antagonism o fthe gastrointestinal ulcerogenic effect of some non-steroidal anti-inflammatory agents by sodium salicylate”,J.Pharm.Pharmac., 28, pp. 655-656 (1976).
Lombardino, et al., “Acidic Antiinflammatory Agents—Correlations of Some Physical, Pharmacological and Clinical Data”,Arzeneim. Forsch. 25 (10), pp. 1629-1635 (1975).
Winter, et al., “Carrageenin-Induced Edema in Hind Paw of the Rat as an Assay for Antiinflammatory Drugs”,Proc.Soc. Exp.Biol.Med., 111, pp. 544-547 (1962).
Brideau, et al., “A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors”,Inflamm. Res. 45, pp. 68-74 (1996).
Ricketts, et al., “Evaluation of selective inhibition of canine cyclooxygenase 1 and 2 by carprofen and other nonsteroidal anti-inflammatory drugs”,AJVR59 (11), pp. 1441-1146 (1998).
Moore, et al., “Tenidap, a structurally novel drug for the treatment of arthritis: Antiinflammatory and analgesic properties”,Inflamm. Res. 45, pp. 54-61 (1996).
Budesinsky, et al., “Nucleophilic substitutions in the 2-methanesulfonylpyrimidine series”,Coll. Czechoslov. Chem Commun. 37, pp. 1721-1733 (1972).
Vane, et al., “Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation”Proc. Natl. Acad. Sci. 91, pp. 2046-2050 (1994).
Rast Bryson
Sakya Subas M.
Berch Mark L.
Habte Kahsay
Hesketh Alan
Pfizer Inc.
Richardson Peter C.
LandOfFree
Hydrazinyl and nitrogen oxide pyrazoles does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydrazinyl and nitrogen oxide pyrazoles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydrazinyl and nitrogen oxide pyrazoles will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3423047